Novo Nordisk A/S Class B (NOVCb)

103.44
-2.18(-2.06%)
  • Volume:
    12,850
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    103.18 - 106.66

NOVCb Overview

Prev. Close
105.62
Day's Range
103.18-106.66
Revenue
157.25B
Open
106.66
52 wk Range
81.07-116
EPS
22.17
Volume
12,850
Market Cap
234.62B
Dividend (Yield)
11.15
(1.45%)
Average Vol. (3m)
13,110
P/E Ratio
35.37
Beta
0.256
1-Year Change
23.11%
Shares Outstanding
2,266,560,505
Next Earnings Date
-
What is your sentiment on Novo Nordisk B?
or
Market is currently closed. Voting is open during market hours.

Novo Nordisk A/S Class B Analysis

Novo Nordisk A/S Class B Company Profile

Novo Nordisk A/S Class B Company Profile

Employees
49295
Market
Denmark
  • Type:Equity
  • Market:Germany
  • ISIN:DK0060534915
  • WKN:A1XA8R

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy
  • Does anyone no of a particular reason that NOVO B is going so far down today? Is it profit taking before Q1 2022 results?
    0
    • New Target 825 by EOM
      0
      • New Target 825
        0
        • Consolidating nicely for leg up to 850!🌟
          0
          • Results from clinical study just published in New England Journal of Medicine: Impressive new weight loss results for Semaglutide at only 2.4 mg once a week. Drug mimics the gut hormone glucagon-like peptide-1 (GLP-1) that is secreted by your gut after eating.
            1
            • Now is the time to buy - novo is very seasonal stock goes up the most in jan/feb.
              0
              • bullish??
                0
                • No. Funds are selling. Time to wait to go long...
                  0
              • Perfect opportunity to make short,,
                1
                • can you explain why please?
                  0
                • No explaning? 🤷
                  0
                • because he has no explanation. Novo nordisk is a soli long-term stock. I know a lot about opioid treatments, and methadon is changing to lipo-methadon, wich has really only one competitor on the global field. That competitor is Camurus AB with their product buvidol. I tecommend to all investors to buy and HOLD for these two companies, because there is no other options for a opioid-replacement-care, except Suboxone, and that is going to be replaced Lipo-methadon or Buvidol, at least here in Finland. Suboxone is manufactured for Indivor Inc, by Aquestive Therapeutics, if someone wants to do a little research.
                  0
              • Bullish sentiment.
                0
                • Why is going so low???
                  0